Medical company Janssen Therapeutics reported on Tuesday the receipt of the US Food and Drug Administration (FDA) approval for the first, complete, single-pill, two-drug regimen JULUCA (Dolutegravir and Rilpivirine) for the treatment of HIV-1 infection in certain adults living with the disease who are virologically suppressed.

According to the company, JULUCA is a once-daily, antiretroviral combination of dolutegravir, an integrase strand transfer inhibitor (INSTI) marketed as TIVICAY, and rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI) marketed as EDURANT for human immunodeficiency virus type 1 (HIV-1) infection.

Through JULUCA, people living with HIV who are virologically suppressed (HIV-1 RNA